StockData
OKYO Pharma Ltd logo

OKYO Pharma Ltd (OKYO) company profile

OKYONasdaqBiological Products, (No Diagnostic Substances)
Số liệu tài chính tới năm tài chính 2026, năm kết thúc ngày Mar 31, 2026Last filing: 20-F on Jul 20, 2026Score 1/30
$1.17−0.18 (-13.33%)

Close on Nov 16, 2026Market cap $61.40MP/E –Yield –

About OKYO Pharma

Biological Products, (No Diagnostic Substances), SIC 2836

OKYO Pharma Limited is a biopharmaceutical company focused on developing treatments for ocular surface and anterior segment diseases. Its primary product candidate is urcosimod, formerly known as OK-101, which is in mid-stage development for neuropathic corneal pain and related conditions. It also advances OK-201, an early-stage therapeutic candidate. Because its pipeline remains in testing, the company generates no commercial product sales. Its prospective customers include patients suffering from ocular diseases and the medical professionals who treat them.

The company is incorporated in Guernsey and maintains its principal executive offices in St. Peter Port. It also maintains an executive presence in London, United Kingdom, and operates through a wholly owned subsidiary, OKYO Pharma Inc. Its developmental and regulatory activities involve the United States, the United Kingdom, and the European Union.

Summary of the business section of OKYO Pharma's latest annual report, written by StockData.

Company profile

Company

Legal name
OKYO Pharma Ltd
Headquarters
London, X0
Address
55 Park Lane W1K 1NA
Phone
44 (0) 207 495 2379
Employees
5, Mar 31, 2026
Industry
Biological Products, (No Diagnostic Substances)
Auditor
PKF Littlejohn LLP, London, England

Stock & identifiers

Ticker
OKYO
Exchange
Nasdaq
IPO date
May 18, 2022
Shares outstanding
52M, Jul 15, 2026
Filer category
Non-accelerated filer<br>Emerging growth company
SEC CIK
1849296
CUSIP
G6724L116
FIGI
BBG015TS35V5
Share class FIGI
BBG015TS36P0
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Robert John DempseyCHIEF EXECUTIVE OFFICER, Director15,000
Gary S. JacobCHIEF DEVELOPMENT OFFICER, Director112,420
Rajkumar V. PatilChief Scientific Officer20,030
Flavio MantelliCHIEF MEDICAL OFFICER20,000
Keeren Rameshchandra ShahChief Financial Officer16,667
Gabriele M. CerroneDirector21,400,332
John P. BrancaccioDirector35,201
Bernard DenoyerDirector–
Willy Jules SimonDirector15,383

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
May 18, 2022
Offer price
$4.00
Securities offered
625,000
Gross proceeds
$2.50M
Exchange
Nasdaq
First trading day
May 17, 2022
First-day close
$3.62-9.5%
Lock-up ends (est.)
Nov 13, 2022

“Our ADSs have been approved for trading on the Nasdaq Capital Market or Nasdaq, under the symbol “OKYO.” The initial public offering price is $4.00 per ADS.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“of March 31, 2026, we had 5 full time employees.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?